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ABSTRACT
Production of trimethylamine-N-oxide (TMAO) via the gut microbiota has recently been
proposed as an important pathophysiological mechanism linking ingestion of ‘unhealthy
foods’, such as beef (containing carnitine) and eggs (containing choline), and the develop-
ment of atherosclerosis. Hence, TMAO has gained attention as a novel biomarker for cardi-
ovascular disease. However, fish and seafood contain considerable amounts of TMAO and are
generally accepted as cardioprotective: a puzzling paradox that seems to have been
neglected. We suspect that the TMAO story may be a red herring.
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Recently published works suggest a causal link
between increased plasma levels of trimethylamine-
N-oxide (TMAO) and increased risk of cardiovascu-
lar disease [1–3]. Plasma TMAO is produced enzy-
mically [by flavin-containing monooxygenase-3
(FMO3)] in the liver by the oxidation of trimethyla-
mine (TMA) generated by the gut microbiota. TMAO
is an odourless compound, whereas TMA has the
smell of spoiled fish. People with a defective FMO3
secrete TMA into their bodily fluids and thus attain a
smell of spoiled fish, a condition designated ‘fish
odour syndrome’ [4].
TMA is produced enzymically (by TMA-lyase)
from the TMA-containing dietary components cho-
line and carnitine by gut bacteria, and after uptake it
is oxidized in the liver to TMAO and excreted.
TMAO has been described as a toxic substance, and
it has been suggested that broad-spectrum inhibitors
of the bacterial TMA-lyase enzymes that generate
TMA – the precursor of TMAO – may ‘revolutionize
the preventive treatment’ of atherosclerotic cardio-
vascular disease [5]. The idea of enriching animal
feeds with TMAO to improve their performance
and growth [6] is, however, not in accordance with
the assumption that TMAO is toxic.
According to the group of Hazen [3], there exists
‘a mechanistic link between intestinal microbe-
dependent generation of trimethylamine-N-oxide
(TMAO) and increased risk for future cardiovascular
events (death, myocardial infarction, and stroke) by a
pathway involving dietary nutrients such as phospha-
tidylcholine, choline, and carnitine’. Fish and other
seafoods contain significant quantities of free TMAO,
in addition to the TMA precursors
(phosphatidylcholine, choline, and carnitine) found
in meat, eggs, and milk products. The role of this
free TMAO has apparently been neglected or over-
looked in the discussion on the possible causal link
between plasma TMAO and risk of cardiovascular
disease. We recently raised this point in a Letter to
the Editor of the Journal of the American College of
Cardiology [7], which was commented upon by Tang
and Hazen [8]. In the following, we extend and ela-
borate on our arguments.
Free TMAO in fish and marine invertebrates
exerts important functions, which largely are asso-
ciated with alleviating protein-denaturing effects of
stressors such as high levels of inorganic ions or
hydrostatic pressure. The molecule plays a particu-
larly crucial role in cartilaginous fishes, where it
counteracts the destabilizing effects of the high intra-
cellular and extracellular concentrations of urea [9].
TMAO has also been associated with provision of
buoyancy for groups of fish that lack a swimbladder
[10]. In cod, a typical representative of a commercial
teleost fish species, the TMAO level in muscle tissue
has been reported to vary between 45 and 50 mmol/
kg [11,12], making the molecule a significant contri-
butor to the pool of cellular osmolytes. Moreover, the
TMAO concentration tends to be several times higher
than this level both in cartilaginous fish species and
in deepwater teleosts [9,12]. By comparison, the total
concentration of choline units (quarternary ammo-
nium groups) in eggs is equivalent to 24 mmol/kg. In
red meat, which has been in focus in the discussion
on the association between plasma TMAO and the
risk of cardiovascular diseases, the choline level
amounts to less than 10 mmol/kg. The only foodstuff
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with a TMA-generating potential from choline equal
to that of TMAO in marine fish species is liver from
bovines and chickens [13]. In red meat, the concen-
tration of carnitine amounts to approximately
6 mmol/kg, i.e. a little more than half of the total
choline concentration. Other foods, including pork
and fish, have levels of carnitine that are only a
fraction of this [14]. Hence, free TMAO in seafood
is quantitatively significantly higher than the amount
of TMAO that can be generated by the gut micro-
biota from choline and carnitine in red meat and
eggs.
Organ et al. [15] have shown, using mouse models,
that TMAO added to feed (0.12%) resulted in a
plasma level of TMAO equivalent to a 10 times
higher admixture of choline. Moreover, TMAO
reaches much higher levels in people on a seafood
diet (> 5000 μmol/l) than those on an egg and red
meat diet (139 μmol/l) [16]. Indeed, urinary TMAO
may even be a biomarker for seafood consumption.
In humans, the plasma level of TMAO increases
rapidly after fish consumption [17], indicating direct
uptake of free TMAO. It is not known, however,
whether all free TMAO in fish is taken up directly
or if some of it is transported into anaerobic com-
partments in the gut. Since TMAO is a preferred
electron acceptor in anaerobic bacterial respiration
[18], any free TMAO in the gut will inevitably be
reduced to TMA by facultative anaerobic bacteria and
thus become a source of TMA that comes in addition
to that generated by TMA-lyase. Whether TMAO is
taken up directly or as TMA after bacterial reduction
of TMAO is, however, of subordinate importance for
the evaluation of TMAO as a risk factor in athero-
sclerosis – seafood results undoubtedly in higher
levels of plasma TMAO than intake of other foods.
If there should be any direct causal link between
plasma TMAO and the risk of cardiovascular dis-
ease, it seems like a paradox that more fish in the
diet reduces this risk [19,20]. Recent randomized
group trials indicate that this effect goes beyond
what can be associated with intake of marine lipids,
since a diet with a large proportion of lean white
fish (rich in TMAO) also reduces the risk [21].
There is, accordingly, an obvious need to clarify
the significance of plasma or urinary TMAO as a
disease marker, but it seems highly unlikely that
free TMAO is the direct cause. Instead, increased
risk of atherosclerosis may be associated with the
abundance of TMA-producing bacteria in the gut,
and hence indirectly with the TMAO generated by
oxidation (i.e. detoxification) of TMA in the liver,
as suggested also by Cho et al. [17]. The same
authors showed that the ratio of Firmicutes to
Bacteriodetes in the gut microbiota was notably
higher in individuals producing high TMAO levels
than in low TMAO producers, hence supporting the
idea that the correlation between TMAO and ather-
osclerosis is indirect and likely to be the result of
dysbiotic gut microbiota. The phenolic antioxidant
resveratrol, often referred to as the anti-
atherosclerosis principle in red wine, inhibits
TMAO production by reduced TMA production
after remodelling the gut microbiota [22].
Bacterial production of TMA from choline and
carnitine is an entirely different biochemical process
from the putative production of TMA from free diet-
ary TMAO. In the latter case, TMAO will be an
electron acceptor in oxidative respiration, with a
high yield of energy for bacterial growth. In the for-
mer case, liberation of TMA from choline and carni-
tine does not generate energy for bacterial growth.
However, the aldehydes produced in the cleavage
reactions are energy-rich substrates in anaerobic fer-
mentation reactions and in respiration. Bacteria pro-
ducing choline TMA-lyase are apparently not very
frequent in the healthy gut microbiota [23] and they
are probably not the same as those able to use TMAO
as an electron acceptor in energy-generating anaero-
bic respiration, and vice versa. Hence, TMA produced
by the different pathways reflects different activities
and composition of the gut microbiota. TMAO pro-
duced in the liver from TMA generated when bac-
teria consume choline and carnitine in the gut may,
therefore, merely be a biomarker of the excessive
presence of particular bacterial species that have
become so abundant that the microbiota has become
dysbiotic.
Optimism has been expressed regarding the pro-
spect of using TMA-lyase inhibitors as new phar-
maceutical drugs against cardiovascular disease [5].
The concept is to reduce TMAO production in the
liver by inhibiting the production of precursor
TMA in the gut. If, however, TMAO as such is a
primary risk factor for atherosclerosis, then such
drugs would be of little help for seafood lovers.
They would have an ample supply of ‘toxic’
TMAO from the healthy food they eat. On the
other hand, free TMAO from seafood may act as
an electron acceptor for facultative anaerobic bac-
teria able to respire with the aldehydes resulting
from the TMA elimination reactions of choline
and carnitine. It may well be that TMAO-rich sea-
food would have the same effect – indirectly – as
the TMA-lyase inhibitors, not by inhibiting TMA-
lyase, but by supporting growth of more beneficial
TMA-producing species. This is, of course, specula-
tion, but seafood is, after all, also known to coun-
teract negative effects of other foods.
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